Table 4 C7 safety in group B subjects.

From: Maximum dose, safety, tolerability and ketonemia after triheptanoin in glucose transporter type 1 deficiency (G1D)

Subject

Glucose (mg/L)

β-hydroxybutyrate (mM)

Lactate (mM)

Cholesterol (mg/dL)

Triglycerides (mg/dL)

Albumin (g/dL)

Pre C7

Post C7

Pre C7

Post C7

Pre C7

Post C7

Pre C7

Post C7

Pre C7

Post C7

Pre C7

Post C7

B1

84

81

0.1

0.1

1.9

1.7

118 L

129

35 L

50

3.3 L

3.2 L

B2

73

81

3.6

1.0

0.9

1.2

178

190

63

76

3.7

3.5 L

B3

82

101

0.8

0.1

0.8

1.4

146

152

47

105

3.5 L

3.4 L

B4

93

92

0.2

0.1

1.1

1.1

62

114

113

138

3.9

3.5 L

B5

83

80

0.1

0.2

1.3

1.1

174

143

117

170 H

3.7

3.4

B6

86

98

2.4

1.0

0.9

1.7

147

154

45

71

3.8

3.5 L

B7

79

88

1.8

0.3

1.4

0.7

216 H

179 H

81

83

3.9

3.8

B8

93

89

1.1

0.4

0.9

1.1

167

171

44

61

3.4 L

3.3 L

B9

92

87

0.6

0.2

1.3

1.8

141

127

51

58

3.5 L

3.3 L

B10

86

86

0.3

0.2

0.8

1.1

124 L

140

74

152 H

3.7

3.7

B11

82

96

0.1

0.1

1.1

2.4

142

144

44

89

4.0

4.1

B12

76

90

0.1

0.1

1.4

1.5

133

138

58

72

3.5 L

3.6

  1. Fasting blood analytes immediately before and 10 days following C7 use in. L: Below reference range; H: Above reference range.